Sintilimab
As of the edition of 20 October 2026, Sintilimab is an antibody: in active development; acts on PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 486, 15 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 31 | 3 | 15 | 0 |
| Phase 1 | 41 | 16 | 8 | 3 |
| Phase 2 | 357 | 32 | 173 | 10 |
| Phase 3 | 54 | 9 | 31 | 2 |
| Phase 4 | 3 | 0 | 3 | 0 |
| All trials | 486 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innovent Biologics | Lead sponsor of trials | 2016 to now |
| Hutchmed | Lead sponsor of trials | 2019 to now |
| Laekna | Lead sponsor of trials | 2022 to now |
| ImmVirx | Lead sponsor of trials | 2023 to now |
| Fujian Haixi Pharmaceuticals | Lead sponsor of trials | 2023 to now |
| RemeGen | Lead sponsor of trials | 2023 to now |